The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Oxaliplatin-Associated Neuropathy: A Review
Abstract
OBJECTIVE: To review the incidence, mechanism, signs, symptoms, and management of oxaliplatin-induced neurotoxicity. DATA SOURCES: English-language publications from the MEDLINE database (1995–August 2004), published articles, and meeting abstracts were reviewed. STUDY SELECTION AND DATA EXTRACTION: Relevant data were extracted from published reports and abstracts on studies and case reports of humans with cancer who received oxaliplatin chemotherapy and in vitro studies of oxaliplatin neurotoxicity. DATA SYNTHESIS: Neurotoxicity is a common adverse effect of oxaliplatin that usually presents as peripheral neuropathy. There are 2 forms of oxaliplatin-induced neurotoxicity: acute and chronic. The acute form occurs in >90% of patients and may begin during the infusion or within hours of completion, is usually self-limited, and may be exacerbated by exposure to cold. Chronic neuropathy is cumulative and is most commonly seen in patients who have received total doses ≥540 mg/m 2. Although it is a sensory neuropathy, the intensity can increase to the point that it impairs physical functions, such as holding objects and writing. Preventive measures include administration of calcium and magnesium solutions, gabapentin, carbamazepine, amifostine, and glutathione. Treatment measures include calcium and magnesium solutions, gabapentin, and α-lipoic acid. CONCLUSIONS: Peripheral neuropathy is seen in the majority of patients who receive oxaliplatin. The acute form is usually transient and self-limited; however, the chronic form can be dose-limiting. Calcium and magnesium solutions are an effective and convenient means of treating and reducing the severity of neuropathic symptoms. Additional studies, including controlled trials, are needed to determine the best way to prevent and treat this complication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham, M. A., Lockwood, G. F., Greenslade, D., Brienza, S., Bayssas, M., & Gamelin, E. (2000) · PubMed · Cited by 455
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Ziegler, D., Hanefeld, M., Ruhnau, K. J., Hasche, H., Lobisch, M., Schütte, K., Kerum, G., & Malessa, R. (1999) · Diabetes Care · doi:10.2337/diacare.22.8.1296 · Cited by 432
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., & Gamelin, E. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.5.2293 · Cited by 344
Cited by
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 648
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?
Carozzi, V. A., Canta, A., & Chiorazzi, A. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.014 · Cited by 431
Animal models of neuropathic pain
Jaggi, A. S., Jain, V., & Singh, N. (2011) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00801.x · Cited by 387
A review on oxaliplatin-induced peripheral nerve damage
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330
Ta, L. E., Espeset, L., Podratz, J., & Windebank, A. J. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.04.010 · Cited by 325
Metadata
- Authors
- Cersosimo, R. J.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 39
- Issue
- 1
- Pages
- 128-135
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2138994529
- Cited by
- 268
- References
- 23
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oxaliplatin-Associated Neuropathy: A Review. https://app.cochat.ai/papers/10.1345/aph.1e319
- The paper
- Cersosimo, R. J. (2005). Oxaliplatin-Associated Neuropathy: A Review. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1e319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.